Autosomal Dominant Polycystic Kidney Disease: A Review.
Chebib FT, Hanna C, Harris PC, Torres VE, Dahl NK.
JAMA. 2025 May 20;333(19):1708-1719. doi: 10.1001/jama.2025.0310.
Narrative review of migraine management in patients with renal or hepatic disease.
Stern JI, Datta S, Chiang CC, Garza I, Vieira DL, Robertson CE.
Headache. 2023 Jan;63(1):9-24. doi: 10.1111/head.14437.
Bioartificial organ support for hepatic, renal, and hematologic failure.
Maguire PJ, Stevens C, Humes HD, Shander A, Halpern NA, Pastores SM.
Crit Care Clin. 2000 Oct;16(4):681-94. doi: 10.1016/s0749-0704(05)70140-8.
Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation.
Renaghan AD, Jaimes EA, Malyszko J, Perazella MA, Sprangers B, Rosner MH.
Clin J Am Soc Nephrol. 2020 Feb 7;15(2):289-297. doi: 10.2215/CJN.08580719. Epub 2019 Dec 13.
Pharmacokinetics of roxithromycin in renal and hepatic failure and drug interactions.
Periti P, Mazzei T.
J Antimicrob Chemother. 1987 Nov;20 Suppl B:107-12. doi: 10.1093/jac/20.suppl_b.107.
Acute Liver Failure.
Rajaram P, Subramanian R.
Semin Respir Crit Care Med. 2018 Oct;39(5):513-522. doi: 10.1055/s-0038-1673372. Epub 2018 Nov 28.
Impact of hepatic impairment and renal failure on the pharmacokinetics of linezolid and its metabolites: contribution of hepatic metabolism and renal excretion.
Liu J, Pang Y, Li W, Sun J, He Y, Guo Y, Dong J.
Antimicrob Agents Chemother. 2025 May 7;69(5):e0189224. doi: 10.1128/aac.01892-24. Epub 2025 Apr 14.
Protein intake in renal and hepatic disease.
Ambühl PM.
Int J Vitam Nutr Res. 2011 Mar;81(2-3):162-72. doi: 10.1024/0300-9831/a000056.
Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib.
Yang YO, Fang Y, Wang P, Liu X, Getsy J, Rockich K.
Br J Clin Pharmacol. 2026 May;92(5):1339-1351. doi: 10.1002/bcp.70372. Epub 2025 Dec 8.
Effects of renal failure on drug transport and metabolism.
Sun H, Frassetto L, Benet LZ.
Pharmacol Ther. 2006 Jan;109(1-2):1-11. doi: 10.1016/j.pharmthera.2005.05.010. Epub 2005 Aug 8.
